UC San Diego Health are conducting what they say is the first known randomized, double-blind, placebo-controlled clinical trial examining cannabis as a treatment for acute migraines.
Around 20 participants are already enrolled in the trial, with the aim to reach 90 participants aged 21-65. The participants are provided four different treatments to be self-administered for four separate migraine attacks – one based on THC, another on CBD, one with a THC/CBD combination and one a placebo. All treatments will be administered using a vaporiser.
Participants will be self-administering the treatments at the onset of a migraine or as early as possible into the attack – one treatment per attack. Among the outcomes to be measured are freedom from pain and pain relief, and the presence or lack thereof of photophobia (sensitivity to light), phonophobia (sensitivity to sound) and nausea. These will be reported at 1 hour, 2 hours, 24 hours, and 48 hours after administration.
Those enrolling will need to agree to a number of conditions, including not using cannabis outside of the study, abstinence from the use of opioids or barbiturates and not driving a motor vehicle within 4 hours of self-administering treatments provided in the course of the study.
However, more solid scientific evidence is needed to establish cannabis’s efficacy.
The UC San Diego Health clinical trial kicked off in November last year and is expected to run until December this year. Further information on the trial can be viewed here.
The study is certainly needed. It is being funded by the Migraine Research Foundation, which states migraine is the third most prevalent illness in the world and the sixth most disabling. As well as being incredibly painful for patients, healthcare and lost productivity costs associated with the condition are put at as high as $36 billion annually just in the U.S according to the Foundation.